Pharmacokinetics of antiretroviral drugs in infancy
Infancy (from birth until 1 year of age) is a time of rapid changes within the body of a child. These changes affect pharmacokinetics in many ways. The CHER study1 showed that early antiretroviral treatment reduces mortality and disease progression amongst infants acquiring HIV infection before 12 w...
Saved in:
Main Authors: | Helen McIlleron (Author), Hermien Gous (Author) |
---|---|
Format: | Book |
Published: |
AOSIS,
2009-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
by: Roeland E. Wasmann, et al.
Published: (2023) -
Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis
by: Louvina E. van der Laan, et al.
Published: (2021) -
Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs
by: Sara Bettonte, et al.
Published: (2024) -
Pharmacokinetic targets of antiretroviral therapy in children and adolescents
by: Michael N. Neely, et al.
Published: (2013) -
Isotopic Radiolabeling of the Antiretroviral Drug [<sup>18</sup>F]Dolutegravir for Pharmacokinetic PET Imaging
by: Marion Tisseraud, et al.
Published: (2022)